FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097398235> ?p ?o ?g. }

• W2097398235 abstract "Triple-negative breast cancer (TNBC), which is characterized by negativity for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), is a high risk breast cancer that lacks specific targets for treatment selection. Chemotherapy is, therefore, the primary systemic modality used in the treatment of this disease, but reliable parameters to predict the chemosensitivity of TNBC have not been clinically available. A total of 190 TNBC patients who had undergone a curative resection of a primary breast cancer were enrolled. The adjuvant chemotherapy was performed for 138 (73%) of 190 TNBC cases; 60 cases had an anthracyclin-based regimen and 78 a 5-fluorouracil-based regimen. The prognostic value of E-cadherin, Ki67 and p53 expression in the outcome of TNBC patients with adjuvant chemotherapy was evaluated by immunohistochemistry. The adjuvant therapy group, especially those with Stage II TNBC, had a more favorable prognosis than the surgery only group (P = 0.0043), while there was no significant difference in prognosis between the anthracyclin-based regimen and 5-fluorouracil-based regimen. Patients with E-cadherin-negative and Ki67-positive expression showed significantly worse overall survival time than those with either E-cadherin-positive or Ki67-negative expression (P < 0.001). Multivariate analysis showed that the combination of E-cadherin-negative and Ki67-positive expression was strongly predictive of poor overall survival (P = 0.004) in TNBC patients receiving adjuvant chemotherapy. In contrast, p53 status was not a specific prognostic factor. Adjuvant therapy is beneficial for Stage II TNBC patients. The combination of E-cadherin and Ki67 status might be a useful prognostic marker indicating the need for adjuvant chemotherapy in Stage II TNBC patients." @default.
• W2097398235 created "2016-06-24" @default.
• W2097398235 creator A5016525146 @default.
• W2097398235 creator A5020306968 @default.
• W2097398235 creator A5032903747 @default.
• W2097398235 creator A5036000437 @default.
• W2097398235 creator A5041423375 @default.
• W2097398235 creator A5077160140 @default.
• W2097398235 creator A5083323851 @default.
• W2097398235 creator A5089607790 @default.
• W2097398235 date "2011-11-30" @default.
• W2097398235 modified "2023-10-09" @default.
• W2097398235 title "Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67" @default.
• W2097398235 cites W159832622 @default.
• W2097398235 cites W1924355940 @default.
• W2097398235 cites W1963888992 @default.
• W2097398235 cites W1967113048 @default.
• W2097398235 cites W1973896410 @default.
• W2097398235 cites W1974570521 @default.
• W2097398235 cites W1989663680 @default.
• W2097398235 cites W1995224853 @default.
• W2097398235 cites W2000557631 @default.
• W2097398235 cites W2019370680 @default.
• W2097398235 cites W2040436551 @default.
• W2097398235 cites W2059104229 @default.
• W2097398235 cites W2059272061 @default.
• W2097398235 cites W2068503417 @default.
• W2097398235 cites W2070669176 @default.
• W2097398235 cites W2073305155 @default.
• W2097398235 cites W2080509338 @default.
• W2097398235 cites W2080880824 @default.
• W2097398235 cites W2083803850 @default.
• W2097398235 cites W2087179076 @default.
• W2097398235 cites W2097255042 @default.
• W2097398235 cites W2116760308 @default.
• W2097398235 cites W2117546979 @default.
• W2097398235 cites W2119480061 @default.
• W2097398235 cites W2119975486 @default.
• W2097398235 cites W2122289625 @default.
• W2097398235 cites W2124580184 @default.
• W2097398235 cites W2130900820 @default.
• W2097398235 cites W2131994307 @default.
• W2097398235 cites W2137935883 @default.
• W2097398235 cites W2138474420 @default.
• W2097398235 cites W2142221925 @default.
• W2097398235 cites W2149011079 @default.
• W2097398235 cites W2156604663 @default.
• W2097398235 cites W2157840751 @default.
• W2097398235 cites W2161426850 @default.
• W2097398235 cites W2165432902 @default.
• W2097398235 cites W2165884472 @default.
• W2097398235 cites W2170556339 @default.
• W2097398235 cites W2172260314 @default.
• W2097398235 cites W2321753125 @default.
• W2097398235 cites W2324864477 @default.
• W2097398235 cites W2330419910 @default.
• W2097398235 cites W3021359142 @default.
• W2097398235 cites W4301025370 @default.
• W2097398235 doi "https://doi.org/10.1186/bcr3068" @default.
• W2097398235 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3326564" @default.
• W2097398235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22126395" @default.
• W2097398235 hasPublicationYear "2011" @default.
• W2097398235 type Work @default.
• W2097398235 sameAs 2097398235 @default.
• W2097398235 citedByCount "60" @default.
• W2097398235 countsByYear W20973982352012 @default.
• W2097398235 countsByYear W20973982352013 @default.
• W2097398235 countsByYear W20973982352014 @default.
• W2097398235 countsByYear W20973982352015 @default.
• W2097398235 countsByYear W20973982352016 @default.
• W2097398235 countsByYear W20973982352017 @default.
• W2097398235 countsByYear W20973982352018 @default.
• W2097398235 countsByYear W20973982352019 @default.
• W2097398235 countsByYear W20973982352020 @default.
• W2097398235 countsByYear W20973982352021 @default.
• W2097398235 countsByYear W20973982352022 @default.
• W2097398235 countsByYear W20973982352023 @default.
• W2097398235 crossrefType "journal-article" @default.
• W2097398235 hasAuthorship W2097398235A5016525146 @default.
• W2097398235 hasAuthorship W2097398235A5020306968 @default.
• W2097398235 hasAuthorship W2097398235A5032903747 @default.
• W2097398235 hasAuthorship W2097398235A5036000437 @default.
• W2097398235 hasAuthorship W2097398235A5041423375 @default.
• W2097398235 hasAuthorship W2097398235A5077160140 @default.
• W2097398235 hasAuthorship W2097398235A5083323851 @default.
• W2097398235 hasAuthorship W2097398235A5089607790 @default.
• W2097398235 hasBestOaLocation W20973982351 @default.
• W2097398235 hasConcept C121608353 @default.
• W2097398235 hasConcept C126322002 @default.
• W2097398235 hasConcept C143998085 @default.
• W2097398235 hasConcept C146357865 @default.
• W2097398235 hasConcept C151730666 @default.
• W2097398235 hasConcept C2776694085 @default.
• W2097398235 hasConcept C2777863537 @default.
• W2097398235 hasConcept C2777982462 @default.
• W2097398235 hasConcept C2780110267 @default.
• W2097398235 hasConcept C2780140570 @default.
• W2097398235 hasConcept C2781413609 @default.
• W2097398235 hasConcept C530470458 @default.
• W2097398235 hasConcept C71924100 @default.

• next